Big pharma shakeup: Lupin sells women’s health arm for mega millions

Lupin Limited, a global pharmaceutical leader, has officially divested its U.S. Commercial Women’s Health Specialty Business to Evofem Biosciences, Inc., a company specializing in women’s health. This strategic move involves the transfer of the commercial rights for SOLOSEC (secnidazole) 2g oral granules, a single-dose antimicrobial treatment for bacterial vaginosis (BV) and trichomoniasis.

Under the terms of the acquisition, Lupin could receive up to $84 million based on future contingent milestones. This divestment aligns with Lupin’s strategic objective to focus on specialty areas such as respiratory and neurological diseases, where it sees greater synergy and potential for growth.

Dr. Fabrice Egros, President of Global Corporate Development at Lupin, expressed satisfaction with the divestment, stating, “We are very pleased to divest our U.S. Commercial Women’s Health Specialty business, including SOLOSEC, to Evofem. This divestment is another step in aligning our U.S. specialty business with our strategic plan to build our specialty business in therapeutic areas where we have building blocks of synergy.”

Evofem’s CEO, Saundra Pelletier, commented on the acquisition’s strategic fit, noting, “The acquisition of this commercial business aligns with and advances our mission to improve access to innovative and differentiated options that impact women’s daily lives. SOLOSEC is a commercially attractive, single-dose oral antibiotic that addresses two pervasive sexual health infections. We can now fully leverage our commercial infrastructure, maximize our strong physician relationships, and re-launch an asset with tremendous growth potential.”

This transaction highlights a significant realignment in the pharmaceutical industry, emphasizing Lupin’s strategic shift towards specialty areas and Evofem’s commitment to enhancing women’s health solutions.